Catalent breaks ground on WI expansion to support commercial biomanufacturing
The $34m expansion at its Madison, Wisconsin site will support Phase III and commercial biologics production, says Catalent.
The $34m expansion at its Madison, Wisconsin site will support Phase III and commercial biologics production, says Catalent.
UPDATE
GE Healthcare says a $7m investment will triple clean-room capacity and add automated production lines at its single-use tech manufacturing facility in Massachusetts.
Pfizer has said it will stop working on bococizumab and cease late phase trials of the monoclonal antibody (mAb) cholesterol buster being run by Ireland-based CRO, Icon.
Lonza has opened a drug quality testing and formulation laboratory in Basel, Switzerland.